Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03100136 · ClinicalTrials.gov registry record · Phase 1
Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03100136: Completed Phase 1 study, sponsored by Pfizer.
NCT03100136 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03100136, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a study measuring the binding kinetics and test-retest characteristics of a subpharmacological dose of \[11C\]PF-06809247 Monoacylglycerol lipase (MAGL) Positron Emission Tomography (PET) tracer in healthy adult subjects.
Primary Outcome
Binding of \[11C\]PF-06809247 will be assessed by the evaluation of net uptake rate constant Ki (mL/min/g) in the various brain regions modeled, as data permit.
Interventions
- DRUG [11C]PF-06809247
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-11-16 |
| Est. Completion | 2017-03-10 |
| Phase | Phase 1 |
What the finished NCT03100136 record still lists
NCT03100136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which [11C]PF-06809247 is the first listed.
NCT03100136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03100136 about?
NCT03100136 is a clinical study titled "Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer". This is a study measuring the binding kinetics and test-retest characteristics of a subpharmacological dose of \[11C\]PF-06809247 Monoacylglycerol lipase (MAGL) Positron Emission Tomography (PET) tracer in healthy adult subjects.
What is the current status of trial NCT03100136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-11-16. Estimated completion is 2017-03-10.
What interventions are being tested in trial NCT03100136?
The interventions under investigation include: [11C]PF-06809247 (DRUG).
Who is sponsoring clinical trial NCT03100136?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03100136's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI